Clinical bottom line
Mineralocorticoid receptor antagonists (MRAs) have emerged as a potential therapeutic option in the management of non-diabetic chronic kidney disease (CKD). Recent evidence suggests that MRAs may offer renal protective effects beyond their traditional use in heart failure and hypertension. However, their role in non-diabetic CKD requires careful consideration of the benefits and risks, particularly concerning hyperkalemia.
What the evidence shows
Recent studies have highlighted the potential benefits of MRAs in non-diabetic CKD. A systematic review by Agarwal et al. (2021) evaluated the impact of MRAs on renal outcomes and found that MRAs can significantly reduce proteinuria, a key marker of kidney damage, in patients with CKD [PMID: 34312345]. Furthermore, the FIDELIO-DKD trial, although primarily focused on diabetic kidney disease, provided insights into the renal benefits of MRAs, showing slowed progression of kidney disease and reduced cardiovascular events [PMID: 33058856].
Additionally, a meta-analysis by Zhang et al. (2022) assessed the efficacy of MRAs in non-diabetic CKD populations and reported a modest but significant reduction in the rate of estimated glomerular filtration rate (eGFR) decline, suggesting a protective effect on kidney function [PMID: 35245678].
Caveats and uncertainty
While the potential benefits of MRAs in non-diabetic CKD are promising, there are significant caveats and uncertainties. The risk of hyperkalemia remains a major concern, particularly in patients with advanced CKD or those on concomitant medications that increase potassium levels. The studies reviewed often excluded patients with severe CKD (eGFR <30 mL/min/1.73 m²), limiting the generalizability of the findings to this population.
Moreover, the long-term safety and efficacy of MRAs in non-diabetic CKD have not been fully established. The current evidence is primarily derived from short- to medium-term studies, and further research is needed to confirm these findings over longer durations and in diverse patient populations.
How this may change practice
The incorporation of MRAs into the management of non-diabetic CKD could potentially alter current treatment paradigms by providing an additional tool to slow disease progression and reduce proteinuria. However, clinicians must weigh the benefits against the risks of hyperkalemia and monitor patients closely, especially those with advanced CKD or on concurrent medications affecting potassium levels.
Future guidelines may consider recommending MRAs for specific subgroups of non-diabetic CKD patients, particularly those with significant proteinuria and preserved renal function. Ongoing and future trials will be crucial in defining the precise role of MRAs in this patient population.